---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-042449"
form_type: "8-K"
ticker: null
cik: "0000793171"
company_name: "Vitro Biopharma, Inc."
filed_at: "2023-11-22T23:59:59+00:00"
generated_at: "2026-06-07T22:26:02.930696+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vitro BioPharma raises $2M via convertible note with 20% OID, warrants, and consulting deal

## Summary
- Issued $2.5M principal senior secured convertible note for $2M cash (20% OID); 20% annual interest, matures May 16, 2024 (extendable to Aug 16).
- Warrants to purchase common stock, exercisable for 5 years; exercise price based on liquidity event or $95M valuation if no event.
- Engaged Alchemy Advisory for 6-month consulting; paid $50K cash, $50K upon IPO/direct listing, and 20K shares (or $300K worth if IPO <$15).
- Note secured by all company assets; conversion price equals 70% of liquidity event price (60% if extended) or $95M/fully-diluted shares.
- Registration rights agreement filed to register resale of conversion and warrant shares within 30 days.

## SEC filing metadata
- accession: 0001493152-23-042449
- form_type: 8-K
- cik: 0000793171
- company_name: Vitro Biopharma, Inc.
- filed_at: 2023-11-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/793171/000149315223042449/0001493152-23-042449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/793171/000149315223042449/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-042449
- JSON: https://secwatch.observer/filing/0001493152-23-042449.json
- Plain text: https://secwatch.observer/filing/0001493152-23-042449.txt

## Key facts
- Debt Financings
  Vitro Biopharma, Inc. incurred convertible notes of $2,500,000 with an accredited investor at 20% maturing May 16, 2024.
  - Instrument: convertible notes
  - Principal: $2,500,000
  - Counterparty: an accredited investor
  - Rate: 20%
  - Maturity: May 16, 2024
  - Event: incurrence
  source text: On November 16, 2023, Vitro BioPharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) a senior secured convertible note (the “Note”) in the principal amount of $2,500,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/793171/000149315223042449/0001493152-23-042449-index.htm
- Material Agreements
  Vitro Biopharma, Inc. entered into Purchase Agreement with an accredited investor (effective 2023-11-16).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an accredited investor
  - Effective: 2023-11-16
  source text: On November 16, 2023, Vitro BioPharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor
  evidence_url: https://www.sec.gov/Archives/edgar/data/793171/000149315223042449/0001493152-23-042449-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.